Skip to main navigation Skip to search Skip to main content

Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status

  • Ho Won Kang
  • , Ye Hwan Kim
  • , Pildu Jeong
  • , Cheol Park
  • , Won Tae Kim
  • , Dong Hee Ryu
  • , Eun Jong Cha
  • , Yun Sok Ha
  • , Tae Hwan Kim
  • , Tae Gyun Kwon
  • , Sung Kwon Moon
  • , Yung Hyun Choi
  • , Seok Joong Yun
  • , Wun Jae Kim
  • Chungbuk National University
  • Kyungpook National University
  • Chung-Ang University
  • Dongeui University

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing and FGFR3 mRNA expression level was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The results were compared with the clinicopathological parameters, and the prognostic value of FGFR3 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression test. FGFR3 mutations were identified in 48/120 (40.0%) patients with pT1 BC. FGFR3 mRNA expression level was significantly higher in those with BC harboring FGFR3 mutations (P<0.001). Low FGFR3 expression level was associated with high-grade tumors and cancer progression (P=0.006 and P=0.001), whereas FGFR3 mutation status was not associated with cancer progression. Kaplan-Meier analysis revealed a similar result (log-rank, P<0.001). Multivariate analysis identified low FGFR3 expression level (odds ratio, 3.300; 95% confidence interval, 1.310-8.313; P=0.011) as an independent predictor of cancer progression. Stratification by exon site of FGFR3 mutations yielded significant differences in mRNA expression level. None of the patients with BC harboring FGFR3 mutations in exon 9 demonstrated disease progression. The mRNA expression level of the FGFR3 gene may be used to precisely identify subsets of patients with pT1 BC that have a relatively better prognosis. The prognostic influences of FGFR3 mutations may be modulated by the exon site of FGFR3 mutations.

Original languageEnglish
Pages (from-to)3817-3824
Number of pages8
JournalOncology Letters
Volume14
Issue number3
DOIs
StatePublished - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bladder cancer
  • Expression
  • Fibroblast growth factor receptor 3
  • Mutation
  • Prognosis

Fingerprint

Dive into the research topics of 'Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status'. Together they form a unique fingerprint.

Cite this